Yes, the patient can remain on cephalexin (Keflex)
If a wound culture shows susceptibility to cefazolin and the patient is already on cephalexin, continuing cephalexin is appropriate and clinically reasonable. Both are first-generation cephalosporins with similar antimicrobial spectra, and switching would provide no meaningful clinical benefit.
Rationale for Continuing Cephalexin
Antimicrobial Equivalence
- Cephalexin and cefazolin share nearly identical antimicrobial coverage against gram-positive cocci (particularly Staphylococcus aureus) and common gram-negative organisms
- Research demonstrates that cephalexin is non-inferior to cefazolin for skin and soft tissue infections, with failure rates of 4.2% vs 6.1% respectively at 72 hours 1
- In vitro susceptibility studies show cefazolin is slightly more effective against gram-positive cocci (71.8% sensitive) compared to cephalexin (52.7%), but both remain clinically effective first-line agents 2
Practical Clinical Considerations
- The primary difference is route of administration: cefazolin requires IV access while cephalexin is oral
- If the patient is tolerating oral therapy and showing clinical improvement, there is no reason to switch to IV therapy
- Cephalexin has a superior side effect profile compared to alternative antibiotics 3
- Both drugs require similar dosing adjustments in renal impairment 4, 5
When to Consider Switching
You should only consider changing antibiotics if:
- Clinical failure: No improvement or worsening after 48-72 hours on cephalexin
- Severe infection requiring IV therapy: Deep tissue involvement, systemic toxicity, or inability to tolerate oral medications
- Specific susceptibility concerns: If the culture shows borderline susceptibility or the organism has higher MICs to cephalexin specifically (though this would typically be reported)
- Patient cannot tolerate oral medications: Nausea, vomiting, or malabsorption issues
Important Caveats
- Monitor for treatment failure: Both drugs can lead to overgrowth of nonsusceptible organisms with prolonged use 4, 5
- Complete the full course: Skipping doses or incomplete therapy increases resistance risk 5
- Watch for C. difficile: Any antibiotic can cause severe diarrhea even weeks after completion 5
- Renal function: Both require dose adjustment in renal impairment, with cefazolin potentially requiring more careful monitoring in elderly patients 4
The key principle here is that susceptibility to cefazolin predicts susceptibility to cephalexin given their shared antimicrobial class and similar mechanisms of action. Unless there are specific clinical reasons to escalate or change therapy, continuing the current effective oral regimen is the most practical approach.